Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup

Ryan Cross

Senior Science Correspondent

Andrew Dunn

Senior Biopharma Correspondent

Earlier Tuesday, Endpoints News reported that former Stanford president Marc Tessier-Lavigne will lead one of biotech’s biggest-ever startup launches: Xaira Therapeutics, which has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup

Ryan Cross

Senior Science Correspondent

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Pfizer partners with two more Flagship biotechs on obesity, cancer

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy

Are programs with compounded GLP-1s safe for your population?

Ex­clu­sive: Marc Tessier-Lav­i­gne on leav­ing Stan­ford and join­ing biotech’s new AI mega-start­up

Senior Science Correspondent

Senior Biopharma Correspondent

Sign up to read this article for free.

Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup